| Literature DB >> 25048263 |
Lihong Wu1, Wen Liu, Nashun Bayaer, Weiwang Gu, Jieli Song.
Abstract
Obesity is a public health problem that increases the risk of metabolic disease, infertility, and other chronic health problems. The present study aimed to develop a new rat model for sex hormone disorder with overweight and Ca loss by intramuscular injection of exogenous leptin (LEP). Thirty female Sprague-Dawley (SD) rats (40 days old) were injected thrice intramuscularly with LEP or keyhole limpet hemocyanin immunogen. The following analyses were performed to determine the development of appetite, overweight, reproductive related-hormones, and calcium (Ca)/phosphorus (Pi) in SD rats: measurement of Lee's index, body weight, food intake; serum Ca, Pi, and hormone tests by enzyme-linked immunosorbent analysis; histological analysis of abdominal fat; real-time polymerase chain reaction analysis of neuropeptide Y, pro-opiomelanocortin, gonadotropin-releasing hormone (Gnrh) mRNA, and gonadotropin-releasing hormone receptor (Gnrhr) mRNA expression; and western blotting analysis of enzyme phosphatidylinositol-3-kinase (PI3K). Rats injected with LEP immunogen displayed significantly increased body weight, food intake, Lee's index, serum LEP, serum cortisol, fat deposition in the abdomen, and decreased hormones including follicle stimulating hormone, luteinizing hormone, estradiol, cholecystokinin, and Ca. Exogenous LEP administered intramuscularly also downregulate Gnrh and PI3K. In conclusion, exogenous LEP administered intramuscularly is a novel animal model for sex hormones disorder with overweight and Ca loss in SD rats. The downregulation of PI3K and Gnrh may be involved in the development of this animal model.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25048263 PMCID: PMC4244293 DOI: 10.1538/expanim.63.447
Source DB: PubMed Journal: Exp Anim ISSN: 0007-5124
Fig. 1.The intramuscular injection of exogenous leptin stimulated a high immune reaction against leptin and induced hyperleptinemia hyperleptindemiahhhyperleptin in rats. (A) Experimental flow chart. Arrows indicate the experimental treatment and data collection time points; (a) body weight; (b) food intake; (c) nose-to-anus length; (d-1) blood sample collection for antibody titer; (d-2) blood sample collection for antibody titer, reproductive function-related hormone, cholecystokinin, calcium, phosphorus; (e) euthanasia for weighing abdominal fat, histological analysis of abdominal fat, real-time polymerase chain reaction analysis of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor in the hypothalamus, and western blotting for phosphatidylinositol-3-kinase in hypothalamus. (B) Anti-leptin antibody titer. (C) Level of serum leptin at the end of the experiment. Asterisks indicate significant differences between treatments (*P<0.05, **P<0.001). All values (mean ± standard error) were derived on a single-day basis of 15 animals per group.
Fig. 2.Intramuscular injection of exogenous leptin increased body weight, Lee’s index, and abdominal fat deposition. (A) body weight; (B) Lee’s index; (C) representative images of abdominal fat of KLH and LEP. All values (mean ± SEM) were derived on a single-day basis of 15 animals per group. Arrows indicate immunogen inoculations; asterisks indicate significant differences between treatments (*P<0.05, **P<0.001). Bar=20 µm.
Fat deposition in abdomen at the end of the experiment
| KLH (n = 15) | LEP (n = 15) | |
|---|---|---|
| Abdominal fat weight (g) | 4.18 ± 0.40 | 5.95 ± 0.35** |
| Abdominal fat (%) | 1.81 ± 0.18 | 2.24 ± 0.11 |
| Abdominal fat cell area (mm2) | 112.27 ± 14.97 | 152.44 ± 7.91* |
| Abdominal fat cell number | 76.17 ± 4.33 | 59.83 ± 4.09* |
Data are presented as mean ± SEM. *P<0.05 vs. KLH, **P<0.001 vs. KLH. KLH, keyhole limpet hemocyanin; LEP, leptin.
Fig. 3.Intramuscular injection of exogenous leptin increased food intake by inhibiting cholecystokinin (CCK) secretion. (A) food intake; (B) level of serum CCK at the end of the experiment; (C) pro-opiomelanocortin (Pomc) and neuropeptide Y (Npy) mRNA expression; (D) ratio of Pomc/Npy. Asterisks indicate significant differences between treatments (*P<0.05, **P<0.001). All values (mean ± SEM) were derived on a single-day basis of 15 animals per group.
Levels of serum reproduction-related hormones at Days 0 and 52
| KLH (n = 15) | LEP (n = 15) | ||||
|---|---|---|---|---|---|
| Day 0 | Day 52 | Day 0 | Day 52 | ||
| FSH (mIU/ml) | 3.97 ± 0.74 | 6.22 ± 0.45 | 3.55 ± 0.57 | 4.14 ± 0.51* | |
| LH (mIU/ml) | 3.26 ± 0.61 | 4.42 ± 0.36 | 3.36 ± 0.52 | 3.23 ± 0.39* | |
| P (ng/ml) | 0.73 ± 0.06 | 1.21 ± 0.21 | 0.78 ± 0.1 | 1.05 ± 0.1 | |
| PRL (ng/ml) | 2.88 ± 0.38 | 5.54 ± 0.45 | 2.75 ± 0.43 | 5.11 ± 0.5 | |
| E2 (pg/ml) | 6.31 ± 1.23 | 17.38 ± 1.44 | 6.78 ± 0.85 | 13.23 ± 1.16* | |
| T (ng/ml) | 466 ± 104 | 1,148 ± 119 | 478 ± 62 | 1,517 ± 108* | |
| IGF1 (ng/ml) | 1,160 ± 239 | 1,241 ± 405 | 1,574 ± 278 | 1,157 ± 264* | |
| Cortisol (ng/ml) | 4.35 ± 0.48 | 5.67 ± 0.85 | 4.06 ± 0.66 | 8.02 ± 0.53* | |
| GH (ng/ml) | 6.98 ± 0.73 | 3.81 ± 0.5 | 7.61 ± 0.64 | 3.61 ± 0.47 | |
Data are presented as mean ± SEM. *P<0.05 vs. KLH. KLH, keyhole limpet hemocyanin; LEP, leptin; FSH, follicle-stimulating hormone; LH, luteinizing hormone; P, progesterone; PRL, prolactin; E2, estradiol; T, testosterone; IGF1, insulin-like growth factor-1; GH, growth hormone.
Serum Ca loss in LEP-immunized rat at the end point of the experiment
| KLH (n = 15) | LEP (n = 15) | ||||
|---|---|---|---|---|---|
| Day 0 | Day 52 | Day 0 | Day 52 | ||
| Ca (mmol/l) | 2.68 ± 0.42 | 2.18 ± 0.42 | 2.74 ± 0.33 | 0.8 ± 0.06* | |
| Pi (mmol/l) | 3 ± 0.36 | 2.04 ± 0.19 | 2.88 ± 0.36 | 1.97 ± 0.2 | |
| Ca/Pi | 0.91 ± 0.1 | 1.13 ± 0.25 | 0.96 ± 0.04 | 0.42 ± 0.04* | |
| Ca × Pi | 8.53 ± 2.1 | 4.31 ± 0.73 | 8.47 ± 2.02 | 1.59 ± 0.23* | |
Data are presented as mean ± SEM. *P<0.05 vs. KLH. Ca, calcium; Pi, phosphorous.
Fig. 4.Real-time polymerase chain reaction analysis of gonadotropin-releasing hormone (Gnrh) and gonadotropin-releasing hormone receptor (Gnrhr) mRNA expression (A) and western blotting analysis of phosphatidylinositol-3-kinase signaling (PI3K) (B) and gray levels of PI3K/β-actin in KLH and LEP group (C). Double asterisks indicate significant differences between treatments (**P<0.001). All values (mean ± SEM) were derived on a single-day basis of 15 animals per group.